Medicare to Reduce Prices on 15 High-Cost Prescription Drugs
The Centers for Medicare & Medicaid Services announced plans to lower prices on 15 expensive prescription drugs, including Ozempic and Wegovy, as part of the Medicare drug price negotiation program.
The Centers for Medicare & Medicaid Services (CMS) has announced plans to reduce prices on 15 high-cost prescription drugs under Medicare, including treatments such as Ozempic and Wegovy. This initiative is part of the Medicare drug price negotiation program established by the Inflation Reduction Act, signed into law in 2022.
This marks the second round of negotiations, following an initial agreement on 10 prescription drugs last year, with price reductions set to take effect in 2026. The newly negotiated prices for the additional 15 drugs are scheduled to be implemented in 2027.
Health and Human Services Secretary Robert F. Kennedy Jr. emphasized the administration's commitment to lowering healthcare costs, stating,
"President Trump directed us to stop at nothing to lower health care costs for the American people. As we work to Make America Healthy Again, we will use every tool at our disposal to deliver affordable health care to seniors."
Drug manufacturers have the option to decline participation in the negotiation program; however, doing so may result in their products being withdrawn from Medicare, one of the nation's largest markets. Legal challenges to the program by pharmaceutical companies have so far been unsuccessful.
The negotiated prices represent what Medicare will pay drugmakers for these medications, not the out-of-pocket costs for patients. According to CMS, these discounts are projected to save taxpayers $12 billion and reduce Medicare enrollees' out-of-pocket expenses by $685 million in 2027.
The 15 drugs selected for price reductions include:
- Ozempic, Rybelsus, and Wegovy (for Type 2 diabetes and weight loss): $274 negotiated price, down from the $959 list price.
- Trelegy Ellipta (asthma treatment): $175, down from $654.
- Xtandi (prostate cancer): $7,004, down from $13,480.
- Pomalyst (chemotherapy): $8,650, down from $21,744.
- Ofev (idiopathic pulmonary fibrosis): $6,350, down from $12,622.
- Ibrance (breast cancer): $7,871, down from $15,741.
- Linzess (chronic constipation): $136, down from $539.
- Calquence (cancer treatment): $8,600, down from $14,228.
- Austedo and Austedo XR (Huntington’s disease): $4,093, down from $6,623.
- Breo Ellipta (COPD): $67, down from $397.
- Xifaxan (diarrhea and irritable bowel syndrome): $1,000, down from $2,696.
- Vraylar (antipsychotic): $770, down from $1,376.
- Tradjenta (diabetes): $78, down from $488.
- Janumet and Janumet XR (diabetes): $80, down from $526.
- Otezla (psoriatic arthritis): $1,650, down from $4,722.
These 15 drugs accounted for $42.5 billion, or 15%, of total Medicare Part D spending in 2024. Medicare Part D covers medications that beneficiaries take at home, as opposed to those administered in a clinical setting.
Stacie Dusetzina, a health policy professor at Vanderbilt University, commented on the negotiations, stating,
"The price negotiations look very reasonable to me. It should hopefully provide some relief for taxpayers and beneficiaries in the long run."
The price reductions come amid widespread concerns about the affordability of prescription drugs in the United States.